López HMA, Herrera ÁW, Sibaja NL, Álvarez VJL

Language: Spanish
References: 22
Page: 219-225
PDF size: 171.79 Kb.

ABSTRACT

Background: Febrile neutropenia is a complication of chemotherapy, with high morbidity and mortality. The condition require treatment with intravenous antibiotics and hospitalización. Now is know that a modality, low-risk febrile neutropenia, could be treated with oral antibiotics out of hospital.
Objective: To compare the frequency of success and days of hospitalization in low-risk FN treated with ceftriaxone-amikacin or fluoroquinolones.
Patients and methods: The trial is prospective, longitudinal, comparative and randomized. We included patients with acute lymphoblastic leukemia without intensive chemotherapy, neutrophils ‹ 0.5 x 10⁹ /L and fever › 38.0°C for more than once for day. A group was treated with amikacin-ceftriaxone; another with gatifloxacin ó moxifloxacin VO. The first group received antibiotics in the hospital; the second was send to home after a day without fever. It was considered successful if remained four consecutive days without fever.
Results: We included 45 patients, 22 and 23. We found no differences between groups in relation to received chemotherapy, initial neutrophils and isolated germs. All patients cured. No one, of the group with fluoroquinolones, presented fever after was sended to home. In all patients the neutrophils increased › 0.5 X 10⁹ /L at the end of treatment. The hospitalization was lower in the group of fluoroquinolones (3.7 and 6.5 days), with p= 0.0001.
Conclusions: In the low-risk FN, treatment with fluoroquinolones is as safe and effective as intravenous antibiotics (ceftriaxone-amikacina), and reduces hospitalization days.

REFERENCES

1. Freifed A, Marchigiani D, Walsh T. A double blind comparison of empirical oral and intravenous antibiotic therapy for low risk febrile patients with neutropenia during cancer chemoterapy. N Engl J Med 1999;341:305-311.

2. Santoloya M, Alvarez A, Becker A. Prospective multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia and fever. J Clin Oncol 2001;19:3415-3421.

3. Blot F, Codonnier C, Buzin A. Severity of illness scores: Are they useful in febrile neutropenic adult patients in hematology wards? A prospective multicenter study. Crit Care Med 2001;29:2125-2131.

4. Sánchez M, Alonso V, Juárez U. Tratamiento de la neutropenia febril secundaria a quimioterapia, con antibióticos orales de modo ambulatorio. Oncología 2004;27(9):533-536.

5. Klastersky J, Paesmans M, Rubenstein E. The Multinational Association for Supportive Care in Cancer Risk Index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-3051.

6. Viscoli C, Castagnola E. Treatment of febrile neutropenia. What is new? Corr Opin Infect Dis 2002;15:377-382.

7. Cruciani M, Malena M, Bosco O. Reappraisal with meta-analysis of the addition of grampositive profilaxis to fluoroquinolone in neutropenic patients. J Clin Oncol 2003;21:4127-4137.

8. Paganini H, Gómez Sandra, Ruvinsky S. Tratamiento ambulatorio secuencial parenteral y oral de niños con neutropenia y fiebre de bajo riesgo de mortalidad. Arch Argent Pediatria 2003;10:31-36.

9. Smith D, Innes H, Reilly S. Oral antibiotic administration and early hospital discharge is a safe and effective alternative for treatment of low risk neutropenic fever. Brit J Can 2003;89:43- 49.

10. Winfried K, Commeta A, Langenaeken J. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 1999;341:312-318.

11. López-Hernández MA, Alvarado IM, Jiménez AR, González AM. La gatifloxacina como monoterapia ¿Es útil en el tratamiento de la neutropenia febril de pacientes con leucemia aguda? Med Int de México 2005;21:176-179.

12. López H, Jiménez A, Borbolla E. Factor estimulante de colonias de granulocitos en el tratamiento de neutropenia febril. Gac Med Mex 2000;136(2):99-105.

13. Bodey GP, Bolivar R, Fainstein V. Infectious complications in leukemic patient. Seminars in Hematology 1982;19(3):193- 226.

14. Gupta A, Swaroop C, Agarwala S, Pandey RM, Bakhshi S. Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia. J Pediatr Hematol Oncol 2009;9:635-641.

15. Kaplinsky C, Drucker M, Goshen J, et al. Ambulatory treatment with ceftriaxone in febrile neutropenic children. J Med Sci 1994;8:649-654.

16. Karthaus M, Egerer G. Ceftriaxone in the outpatient treatment of cancer patients with fever and neutropenia. Eur J Clin microbiol Infect Dis 1998; 7:501-505.

17. Castagnola E, Paola D, Giacchino R, Viscoli C. Clinical and laboratory features predicting a favourable outcome and allowing early discharge in cancer patients with low-risk febrile neutropenia: a literature review. J Hematother Stem Cell Res 2000;9(5):645-649.

18. Imran H, Tleyjeh IM, Arndt CA, et al. Fluoroquinolone prophilaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials. Eur J Clin Microbiol Infect Dis 2008;27(1):53-63.

19. Petrilli A, Altruda CF, Pires PA. Oral gatifloxacina in the outpatient treatment of children with cancer fever and neutropenia. Pediatr Blood Cancer 2007;49(5):682-686.

20. Chamilos G, Bamias A. Outpatient Treatment of Low-Risk Neutropenic Fever in Cancer Patients Using Oral Moxifloxacin. Cancer 2005;103:2629-2635.

21. Taléns-Visconti R, Garrigues TM, Cantón E. Mecanismos de resistencia bacteriana a las quinolonas. Revista Española de Quimioterapia 2002;15(1): 25-27.

22. Calva-Mercado J, Castillo G, López-Vidal Y. Actividad de las fluoroquinolonas en aislamientos clínicos de Streptococcus pneumoniae con diferente susceptibilidad a la penicilina: estudio epidemiológico en cinco ciudades de la República Mexicana. Gac Med Méx 2005;141(4):253-258.